HLA-G and myeloid sarcoma: MS patients had a significantly lower prevalence of SV40 antibodies but a higher prevalence of soluble HLA-G (sHLA-G) molecules as compared to healthy controls, non-MS inflammatory diseases or non-inflammatory neurological diseases [80,81,82].